1-to-1 Reconstruction of Human Tissues

Despite demonstrating high efficacy in cell culture and animal models, over 95% of anticancer drugs do not reach the patients because they fail clinical trials. Reconstructed organ platform is designed to screen compound libraries and evaluate drug candidates and drug combinations within the native microenvironment of human tissues.

Reconstructed organ technology is a patient-derived 3D culture platform that recreates the complex human organ microenvironment thereby preserving the critical interactions between tumor and its surroundings. Reconstructed organ system provides a physiologically relevant system that mimics the biology of human disease, and as such, demonstrates high correlation with clinical response.


Drug candidate screening

Identification of new drug combinations

Rescue failed drug candidates

Target discovery

Biomarker discovery

Evaluation of off-target toxicity

Technology Advantages

Simulates complex human organ environment

Tumor microenvironment, the cellular and extracellular elements that surround cancer cells, protects malignant cells from exogenous insults and renders tumor cells resistant to multiple therapeutic agents. Reconstructed organ platform incorporates both cellular and extracellular elements of tissue microenvironment in an organ- and disease-specific manner.

Extracellular components

  • extracellular matrix (ECM)
  • soluble factors (cytokines, etc.)

Cell-cell interactions

  • tumor-tumor interactions
  • tumor-stroma interactions

Preserves cellular composition

Reconstructed organ platform supports long-term survival and proliferation of malignant and non-malignant cellular components of tissues. This includes tumor cells, stroma, and immune components.

Exhibits high correlation with clinical response

Reconstructed organ exhibits high correlation with clinical response when comparing treatment outcomes in the clinic with cellular behavior in response to the therapeutic regimen. Reconstructed organ is compatible with multiple drug classes, including small molecules, antibodies, antibody-drug conjugates (ADC), immunomodulatory agents, CAR-T cells, etc.

Fully customizable

Reconstructed organ platform is fully customizable to the tumor and tissue of interest. It is compatible with multiple cell types, drug classes, and downstream analysis methods.

Learn More About 3D Cell Culture Systems

Novel 3D Culture Technologies Utilizing Patient-Derived Tissue

Julia Kirshner, Ph.D. 

Human cells have been grown in culture since the 1950s. However, conventional cell culture models lack tissue microenvironment, and thus, have limited physiological relevance. Emerging 3D culture systems are starting to incorporate various components of tissue microenvironment to better replicate the biology of human tissues. zPREDICTA’s reconstructed organ platform mimics the native architecture of human tissues in an organ- and disease-specific manner, and thus, demonstrates high correlation with clinical response. This 45 minute educational webinar will summarize the current state of 3D culture technologies and will highlight relevant applications of each platform.


What readout is compatible with reconstructed organ technology?
Reconstructed organ is compatible with any standard readout techniques, including but not limited to, flow cytometry, microscopy (brightfield, fluorescence, confocal), immunohistochemistry, nucleic acid analysis (RNAseq, qPCR, arrays, etc.), proteomics, cell-based assays (i.e. viability, proliferation, migration, etc.), and in vivo studies.

Cells can be isolated from reconstructed organ using non-enzymatic isolation solution that is compatible with flow cytometry and any other readout strategies that require intact surface receptors. Moreover, cells remain viable after isolation and can be subsequently used in both in vitro and in vivo studies.

Do primary, patient-derived cells maintain their phenotype in reconstructed organ cultures?
Yes. The proportion of each population is retained over the course of the culture (i.e. each cell population present in the patient material is maintained over the course of the culture in the same proportions as present in the starting material).

How long can cells remain viable in reconstructed organ cultures?
Viability of primary, patient-derived cells can be maintained for at least 28 days in reconstructed organ cultures.

What type of therapeutic agents can be tested in reconstructed organ?
Any type of therapeutic agent can be used in reconstructed organ: small molecules, antibodies, antibody-drug conjugates, biologic agents, cell therapeutics (i.e. CAR-T cells).

What is the thickness of reconstructed cultures?
The average thickness of the ECM is 800nm-1mm, which can be modulated depending on the study goals.

Is it possible to do high-resolution imaging and immunohistochemistry (IHC)?
Yes, in-matrix imaging is possible, which retains its native architecture, allowing analysis of cell-cell interactions and analysis of spatial orientation of cells and interactions between different cell types. Immunohistochemistry (IHC) is also possible.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search